Trial · NCT07384416
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
NCT07384416, Phase 2, Recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. QL1706 Plus Lenvatinib in Previously Treated Penile Cancer. Trials, record NCT07384416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07384416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
- NCT number
- NCT07384416
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 47 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Penile Cancer
- Interventions
- QL1706 + Lenvatinib
- First posted
- 2026-02-03
- Last updated
- 2026-05-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | median PFS (median Progression-Free Survival） | From treatment initiation date to first documented disease progression or death from any cause | defined as the median time from study enrollment to the first occurrence of any of the following events: Radiographic disease progression according to RECIST version 1.1, as determined by the investigator; For patients who undergo conversion surgery, postoperative local recurrence or distant metastasis; Death from any cause, whichever occurs first. Conversion surgery itself will not be considered a PFS event. For participants who have not experienced a PFS event at the time of analysis, PFS will be censored at the date of the last tumor assessment or last follow-up. |
| Secondary | ORR (Objective Response Rate） | Baseline to first documented disease progression, death or last valid tumor assessment | |
| Secondary | Disease Control Rate | From baseline until the earliest documented disease progression, death from any cause, or the last valid tumor assessment without prior progression. | The proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1 criteria. |
| Secondary | Duration of Response | Time Frame: From date of first confirmed CR/PR until first documented disease progression or death | The time interval from the first documentation of confirmed CR or PR to the earliest documented disease progression or death from any cause. |
| Secondary | median overall survival | From treatment initiation date to death from any cause | Median Overall Survival (OS) is defined as the median time interval from the date of treatment initiation to the date of death from any cause. For participants who were alive at the last follow-up or lost to follow-up, OS was censored at the date of the last known alive status. |
| Secondary | Adverse Event Rate | From treatment initiation through 30 days after the last study drug administration | The proportion of participants who experience at least one adverse event during the study treatment period and follow-up period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07384416
GET https://conductscience.org/api/trials/v1/NCT07384416/registered